United States Veterinary Vaccines Market Outlook: US$236 Million Opportunity at 8.4% CAGR, Driven by Livestock Immunization & Companion Animal Health

The Global Veterinary Vaccines Market reached US$124 million in 2023 and is expected to reach US$236 million by 2031, growing at a CAGR of 8.4% during the forecast period 2024 to 2031, according to DataM Intelligence.

United States: Recent Industry Developments
✅ In March 2025, Zoetis introduced a new formulation of Vanguard® B Intranasal Vaccine for enhanced protection against Bordetella bronchiseptica in dogs.
✅ In September 2024 (with ongoing impact into 2025), Merck & Co., Inc. expanded its NOBIVAC NXT platform with a groundbreaking RNA-Particle Technology vaccine for Feline Leukemia Virus (FeLV).
✅ In June 2024, Merck Animal Health launched the NOBIVAC NXT Rabies portfolio, including NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies, supporting broader companion animal immunization.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/veterinary-vaccines-market?sindhuri

Japan: Recent Industry Developments
✅ In 2025, Japan continued advancements in companion animal vaccines, with focus on zoonotic disease prevention and pet health awareness under national animal welfare initiatives.
✅ Collaborations with global players like Boehringer Ingelheim and Zoetis for vaccine distribution and R&D to address emerging threats like leptospirosis and rabies.
✅ Ongoing government support for livestock and aquaculture vaccines to ensure food security and export compliance.

Asia-Pacific: Recent Industry Developments
✅ In February 2025, Bharat Biotech received CDSCO license for Biolumpivaxin, a lumpy skin disease vaccine for cattle in India.
✅ In November 2024, Ceva invested in a new vaccine manufacturing plant in Monor, Hungary (with APAC implications for supply chain), expanding inactivated vaccine production.
✅ In 2025, government initiatives in India (e.g., FMD control programs) and China boosted poultry and porcine vaccine adoption amid rising livestock diseases.

Mergers & Acquisitions
✅ October 2023 (ongoing impact): Virbac acquired Globion to strengthen its poultry vaccine portfolio in India.
✅ Strategic alliances and acquisitions among key players like Boehringer Ingelheim and Merck to expand regional presence and technology platforms.

Technological Partnerships
✅ Collaborations between Merck Animal Health and research institutes (e.g., Pirbright Institute) for advanced IBR vaccine development.
✅ Partnerships in mRNA and recombinant platforms, including University of Pennsylvania's mRNA research for canine vaccines.
✅ Global alliances for multi-valent vaccines, such as Boehringer Ingelheim's FLEX CircoPRRS for swine.

New Product/Service Launch
✅ February 2025: Boehringer Ingelheim launched VAXXITEK HVT+IBD+H5 trivalent vaccine for poultry protection against Marek's, Gumboro, and H5 avian influenza.
✅ March 2025: Merck Animal Health introduced SEQUIVITY vaccine advancements.
✅ June 2024: MSD Animal Health launched NOBIVAC NXT Rabies in key markets.

Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/veterinary-vaccines-market?sindhuri

Technological Advancements in the Market
✅ Emergence of mRNA-based and RNA-particle technologies for faster development and better efficacy in companion animals.
✅ Advancements in live attenuated, inactivated, and recombinant vaccines, with focus on multi-disease combination shots to reduce administrations.
✅ Integration of platform technologies like SEQUIVITY for customizable vaccines and improved cold-chain innovations to address storage challenges.

Funding Raised by Companies
✅ Significant R&D investments by major players like Zoetis, Merck, and Boehringer Ingelheim in novel platforms (e.g., RNA and recombinant).
✅ Government-backed funding in India (e.g., over 13,000 crores for FMD programs) and global initiatives supporting vaccine R&D and manufacturing expansions.

Market Dynamics & Key Insights
✅ Rising incidence of livestock and zoonotic diseases, increasing pet ownership, and demand for animal-derived food products driving preventive vaccination.
✅ Government initiatives (e.g., India's Nandi portal, FMD eradication targets) and awareness of zoonotic risks accelerating adoption.
✅ High storage costs, regulatory hurdles, and R&D expenses as restraints, but innovations in recombinant and mRNA vaccines offering growth potential.
✅ Livestock vaccines dominate due to food security needs; companion animals growing fastest with pet humanization trends.

Segmentation
By Vaccine
The Livestock Vaccines segment dominates, including Bovine, Poultry, Porcine, and Others, driven by high disease prevalence and food production demands.
Companion Animal Vaccines (Canine, Feline, Equine) hold significant share, with canine vaccines accounting for ~56.5% globally due to pet ownership growth.
By Type
Live Attenuated Vaccines lead for strong immunity induction.
Inactivated Vaccines, Toxoid, Subunit, Recombinant, and Others follow, with recombinant gaining traction for safety and customization.
By Route of Administration
Injection Vaccines dominate for precise dosing.
Oral and Intranasal/Spray Vaccines growing for ease in poultry and companion animals.
By Distribution Channel
Veterinary Hospitals and Clinics lead.
Retail Pharmacies also contribute.

Regional Analysis
North America leads with ~41.2% share, supported by high livestock/zoonotic disease prevalence, pet insurance, and advanced R&D.
Asia-Pacific is the fastest-growing region, driven by rising livestock production, government programs (e.g., India FMD initiatives), and increasing pet adoption in emerging economies.
Europe holds strong position with regulatory focus and companion animal demand.
South America and Middle East & Africa show gradual growth through improving veterinary infrastructure.

Buy now and enjoy discounts - limited-time offer!
https://www.datamintelligence.com/buy-now-page?report=veterinary-vaccines-market?sindhuri
Competitive Landscape

Key players include Merck & Co., Inc., Zoetis Services LLC, Boehringer Ingelheim International GmbH, Elanco, Ceva, Hester Biosciences Limited, Phibro Animal Health Corporation, Indian Immunologicals Ltd, CZ Vaccines, and Biogénesis Bagó. Companies drive growth through product launches, acquisitions, and innovations in recombinant/mRNA platforms.

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.
Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.

This release was published on openPR.